Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jad Chahoud, Yousef Zakharia, Meredith McKean, Sanjay Goel, Bartosz Chmielowski, Diana L. Hanna, Gregory A. Daniels, Richard Cheng Han Wu, Suthee Rapisuwon, Randolph Hurley, Anurag Gupta, Meghan Duncan, Aigerim Siu, Ekta Patel, Damiano Fantini, David Crowe, Sattanathan Paramasivan, Katarina Luptakova, Howard L. Kaufman, Diwakar Davar
Institutions: Moffitt Cancer Center, University of Iowa Holden Comprehensive Cancer Center, Sarah Cannon, Rutgers Cancer Institute, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of Southern California, USC Norris Comprehensive Cancer Center, Moores Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Georgetown Lombardi Comprehensive Cancer Center, Regions Hospital, HealthPartners, Xilio Therapeutics (United States), Massachusetts General Hospital, UPMC Hillman Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4399600018